Osimertinib (AZD9291)

Name: Osimertinib (AZD9291)
Brand: Selleck Chemicals
SKU: S7297
Rating: 5 (265 reviews)

For research use only.

Catalog No.S7297 Synonyms: Mereletinib

265 publications

Osimertinib (AZD9291) Chemical Structure

CAS No. 1421373-65-0

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

Selleck's Osimertinib (AZD9291) has been cited by 265 publications

Cancer Cell, 2021, S1535-6108(21)00383-4

PubMed: 34388376 ( click the link to review the publication )

Cancer Cell, 2021, S1535-6108(21)00492-X

PubMed: 34624218 ( click the link to review the publication )

Cell, 2020, 182(5):1232-1251.e22

PubMed: 32822576 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cancer Discov, 2015, 5(11):1155-63

PubMed: 26286086 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4789

PubMed: 34373451 ( click the link to review the publication )

Nat Commun, 2021, 12(1):2346

PubMed: 33879767 ( click the link to review the publication )

Nat Commun, 2021, 12(1):5919

PubMed: 34635651 ( click the link to review the publication )

Cancer Res, 2021, canres.1153.2021

PubMed: 34301758 ( click the link to review the publication )

Cancer Res, 2021, canres.CAN-21-2426-E.2021

PubMed: 34548332 ( click the link to review the publication )

Cell Rep, 2021, 37(1):109788

PubMed: 34610309 ( click the link to review the publication )

Cell Rep, 2021, 35(8):109181

PubMed: 34038737 ( click the link to review the publication )

Cell Rep, 2021, 34(3):108647

PubMed: 33472066 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):17

PubMed: 33461557 ( click the link to review the publication )

EBioMedicine, 2021, 64:103220

PubMed: 33529999 ( click the link to review the publication )

Cancers (Basel), 2021, 13(12)2987

PubMed: 34203709 ( click the link to review the publication )

Cancers (Basel), 2021, 13(15)3906

PubMed: 34359807 ( click the link to review the publication )

Arch Toxicol, 2021, 10.1007/s00204-021-03147-4

PubMed: 34455456 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.0965.2020

PubMed: 34158345 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(5):6890-6903

PubMed: 33621951 ( click the link to review the publication )
Pharmacol Res, 2021, 170:105701

PubMed: 34087353 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(8):3659-3670

PubMed: 34584864 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(3):1277-1291

PubMed: 33889509 ( click the link to review the publication )

Cancer Sci, 2021, 112(5):1963-1974

PubMed: 33544933 ( click the link to review the publication )

Cancer Sci, 2021, 112(9):3784-3795

PubMed: 34145930 ( click the link to review the publication )

Cancer Sci, 2021, 112(5):1853-1864

PubMed: 33410241 ( click the link to review the publication )

Oncogenesis, 2021, 10(3):29

PubMed: 33723247 ( click the link to review the publication )

Oncogenesis, 2021, 10(7):56

PubMed: 34315851 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2021, 1868(6):119016

PubMed: 33744274 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2021, 1869(1):119144

PubMed: 34599981 ( click the link to review the publication )

Lung Cancer, 2021, 158:137-145

PubMed: 34214933 ( click the link to review the publication )

Front Oncol, 2021, 11:665045

PubMed: 34168988 ( click the link to review the publication )

Front Oncol, 2021, 11:711043

PubMed: 34490108 ( click the link to review the publication )

Biochem Pharmacol, 2021, 190:114642

PubMed: 34077739 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(8)4005

PubMed: 33924522 ( click the link to review the publication )

Sci Rep, 2021, 11(1):19667

PubMed: 34608255 ( click the link to review the publication )

Acta Pharmacol Sin, 2021, 10.1038/s41401-020-00577-1

PubMed: 33414509 ( click the link to review the publication )

Acta Pharmacol Sin, 2021, 10.1038/s41401-021-00691-8

PubMed: 34035487 ( click the link to review the publication )

Ann Transl Med, 2021, 9(14):1150

PubMed: 34430591 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2021, 419:115518

PubMed: 33812963 ( click the link to review the publication )

Cancer Res Treat, 2021, 10.4143/crt.2021.385

PubMed: 33940786 ( click the link to review the publication )

Toxicol Lett, 2021, 348:10-17

PubMed: 34044055 ( click the link to review the publication )

Biochem Biophys Res Commun, 2021, 571:38-45

PubMed: 34303194 ( click the link to review the publication )

Thorac Cancer, 2021, 12(11):1690-1698

PubMed: 33939301 ( click the link to review the publication )
Thorac Cancer, 2021, 10.1111/1759-7714.13931

PubMed: 33710795 ( click the link to review the publication )

Jpn J Clin Oncol, 2021, hyab048

PubMed: 33829270 ( click the link to review the publication )

Oncol Lett, 2021, 21(5):418

PubMed: 33841579 ( click the link to review the publication )

BMC Pulm Med, 2021, 21(1):163

PubMed: 33992097 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Exp Ther Med, 2021, 21(6):654

PubMed: 33968184 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(1):128-142

PubMed: 33569299 ( click the link to review the publication )

Lung Cancer, 2021, 154:84-91

PubMed: 33631449 ( click the link to review the publication )

NPJ Precis Oncol, 2021, 5(1):65

PubMed: 34267282 ( click the link to review the publication )

EBioMedicine, 2021, 64:103220

PubMed: 33529999 ( click the link to review the publication )

NPJ Precis Oncol, 2021, 5(1):32

PubMed: 33863983 ( click the link to review the publication )

CU Digital Repository, 2021, N/A

PubMed: None ( click the link to review the publication )

Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w

PubMed: 33686255 ( click the link to review the publication )

NPJ Precis Oncol, 2021, 5(1):91

PubMed: 34642436 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Sci Immunol, 2020, 31;5(43) pii: eaav3937

PubMed: 32005679 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Clin Cancer Res, 2020, 20 pii: clincanres

PubMed: 32312893 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2321

PubMed: 31953310 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Theranostics, 2020, 15;10(14):6122-6135

PubMed: 32483443 ( click the link to review the publication )

Cancer Res, 2020, 80(21):4655-4667

PubMed: 32873635 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )
Cancer Lett, 2020, 28;483:46-58

PubMed: 32272148 ( click the link to review the publication )

Cancers (Basel), 2020, 13(1)E111

PubMed: 33396393 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32183160 ( click the link to review the publication )

Cell Death Dis, 2020, 14;11(4):230

PubMed: 32286266 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):214

PubMed: 33033232 ( click the link to review the publication )

Cancer Discov, 2020, 15 pii: CD-20-0116

PubMed: 32414908 ( click the link to review the publication )

Hum Mol Genet, 2020, ddaa268

PubMed: 33326033 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3813-3823

PubMed: 32735723 ( click the link to review the publication )

Lung Cancer, 2020, 5;145:48-57

PubMed: 32408132 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-20-0664

PubMed: 33106373 ( click the link to review the publication )

Front Oncol, 2020, 9:1503

PubMed: 31993373 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.16135

PubMed: 33247550 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Ann Transl Med, 2020, 8(6):366

PubMed: 32355810 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002/tox.22899

PubMed: 31916386 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 534:1-7

PubMed: 33302159 ( click the link to review the publication )

J Oncol, 2020, 17;2020:6249829

PubMed: 32256584 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):169

PubMed: 33287873 ( click the link to review the publication )

Cancer Sci, 2020, 111(7):2374-2384

PubMed: 32391602 ( click the link to review the publication )

Nat Cancer, 2020, 1(3):359-369

PubMed: 33345196 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:652

PubMed: 32793596 ( click the link to review the publication )
Pharmaceutics, 2020, 12(10)E939

PubMed: 33008019 ( click the link to review the publication )

Cells, 2020, 9(12)E2596

PubMed: 33287368 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-0443-1

PubMed: 32704041 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Physiol Rep, 2020, 8(13):e14490

PubMed: 32652816 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-0457-8

PubMed: 32678313 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11236

PubMed: 32641854 ( click the link to review the publication )

Food Funct, 2020, 11(3):2714-2724

PubMed: 32163057 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Rapid Commun Mass Spectrom, 2020, 10.1002/rcm.8955

PubMed: 32990383 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(4):656-671

PubMed: 30578931 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3329-3340

PubMed: 30770351 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz206

PubMed: 31678994 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cell Syst, 2019, 10.1016/j.cels.2019.10.002

PubMed: 31668800 ( click the link to review the publication )

Biomaterials, 2019, 219:119400

PubMed: 31398570 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2808

PubMed: 31806641 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(5):656-670

PubMed: 30171258 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers, 2019, 11(3)

PubMed: 30818860 ( click the link to review the publication )
Signal Transduct Target Ther, 2019,

PubMed: 32651361 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):112-126

PubMed: 30322949 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1593-1601

PubMed: 31253648 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(8):1708-1721

PubMed: 31497352 ( click the link to review the publication )

Lung Cancer, 2019, 127:146-152

PubMed: 30642543 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(11):7427-7437

PubMed: 31454149 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(12):2607-2614

PubMed: 31754333 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:3419-3432

PubMed: 31114376 ( click the link to review the publication )

Ann Transl Med, 2019, 7(22):651

PubMed: 31930052 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 379:114662

PubMed: 31301315 ( click the link to review the publication )

J Cell Biochem, 2019, 120(1):756-767

PubMed: 30145802 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

Thorac Cancer, 2019, 10(10):1868-1878

PubMed: 31486270 ( click the link to review the publication )

Breast Cancer (Dove Med Press), 2019, 11:231-241

PubMed: 31839713 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):955-961

PubMed: 31289574 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(10):1689-1704

PubMed: 31314158 ( click the link to review the publication )
Cell Mol Gastroenterol Hepatol, 2019, 7(1):161-184

PubMed: 30522949 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5692

PubMed: 30952931 ( click the link to review the publication )

Transl Lung Cancer Res, 2019, 8(4):340-351

PubMed: 31555510 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2019, 22(5):264-270

PubMed: 31109435 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4655

PubMed: 30405134 ( click the link to review the publication )

J Thorac Oncol, 2018, 13(7):915-925

PubMed: 29702287 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(22):5610-5621

PubMed: 29967248 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cancer Res, 2018, 10.1158/0008-5472.CAN-18-0505

PubMed: 30026325 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):740-750

PubMed: 29467275 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2257-2265

PubMed: 30049789 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(1):99-109

PubMed: 29269566 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

Nanomedicine (Lond), 2018, 13(10):1107-1120

PubMed: 29874151 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )
Front Cell Neurosci, 2018, 12:21

PubMed: 29456493 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(3):239-247

PubMed: 29333953 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2018, 10.1007/s00432-018-2668-7

PubMed: 29797219 ( click the link to review the publication )

Cancer Med, 2018, 7(1):208-218

PubMed: 29239135 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):1046-1054

PubMed: 29917169 ( click the link to review the publication )

Environ Toxicol, 2018, 33(11):1153-1159

PubMed: 30136359 ( click the link to review the publication )

Radiat Res, 2018, 189(3):283-291

PubMed: 29332537 ( click the link to review the publication )

Pharmazie, 2018, 73(11):630-634

PubMed: 30396380 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

JCI Insight, 2018, 3(24)

PubMed: 30568033 ( click the link to review the publication )

JCI Insight, 2018, 3(11)

PubMed: 29875309 ( click the link to review the publication )

Oncotarget, 2018, 9(101):37520-37533

PubMed: 30680067 ( click the link to review the publication )

Oncotarget, 2018, 9(76):34240-34258

PubMed: 30344940 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

JCI Insight, 2018, 3(24)

PubMed: 30568033 ( click the link to review the publication )

Nanomedicine (Lond), 2018, 13(10):1107-1120

PubMed: 29874151 ( click the link to review the publication )

Oncotarget, 2018, 9(101):37520-37533

PubMed: 30680067 ( click the link to review the publication )

Sci Transl Med, 2017, 9(415)

PubMed: 29118262 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

J Natl Cancer Inst, 2017, 1;109(9):djx014

PubMed: 28376152 ( click the link to review the publication )
J Thorac Oncol, 2017, 12(5):884-889

PubMed: 28088511 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Neuro Oncol, 2017, 19(12):1628-1639

PubMed: 28575494 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2990-3000

PubMed: 28416483 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3527-3539

PubMed: 28522751 ( click the link to review the publication )

Cancer Res, 2017, 10.1158/0008-5472

PubMed: 28202511 ( click the link to review the publication )

Cancer Res, 2017, 77(5):1200-1211

PubMed: 28082405 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.21536

PubMed: 28199182 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):357-364

PubMed: 27913578 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(3):506-515

PubMed: 28138027 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 27913578 ( click the link to review the publication )

Mol Oncol, 2017,

PubMed: 28388009 ( click the link to review the publication )

J Mol Biol, 2017, 429(14):2211-2230

PubMed: 28539250 ( click the link to review the publication )

Eur J Med Chem, 2017, 140:510-527

PubMed: 28987609 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(7):915-928

PubMed: 28289161 ( click the link to review the publication )
Mol Cancer Res, 2017, 15(11):1542-1550

PubMed: 28784613 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(7):852-861

PubMed: 28314843 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

Lung Cancer, 2017, 108:96-102

PubMed: 28625657 ( click the link to review the publication )

Lung Cancer, 2017, 109:1-8

PubMed: 28577937 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Clin Lung Cancer, 2017, 18(3):281-285

PubMed: 28038979 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 321:18-26

PubMed: 28237877 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5281-5288

PubMed: 29138581 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

J Vis Exp, 2017, (126)

PubMed: 28829429 ( click the link to review the publication )

Oncotarget, 2017, 8(62):105479-105491

PubMed: 29285266 ( click the link to review the publication )

Oncotarget, 2017, 8(41):70736-70751

PubMed: 29050315 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36331-36338

PubMed: 28422737 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109319-109331

PubMed: 29312610 ( click the link to review the publication )

Oncotarget, 2017, 8(62):104894-104912

PubMed: 29285221 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15441

PubMed: 29133857 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29050315 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )
Oncotarget, 2017, 8(22):36331-36338

PubMed: 28422737 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Mol Cell, 2016, 63(3):526-38

PubMed: 27453044 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )

Cancer Immunol Res, 2016, 4(11):936-947

PubMed: 27680026 ( click the link to review the publication )

Oncogene, 2016, 10.1038/onc.2016.216

PubMed: 27345413 ( click the link to review the publication )

J Med Chem, 2016, 59(13):6187-200

PubMed: 27266526 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(12):3040-3054

PubMed: 27612490 ( click the link to review the publication )

Cancer Sci, 2016, 107(8):1134-40

PubMed: 27240419 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84951-84964

PubMed: 27825114 ( click the link to review the publication )

Oncotarget, 2016, 7(30):47998-48010

PubMed: 27384992 ( click the link to review the publication )

Oncotarget, 2016, 7(17):23608-32

PubMed: 27015562 ( click the link to review the publication )

Sci Rep, 2016, 6:37997

PubMed: 27897231 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(23):5305-13

PubMed: 26206867 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Sci Signal, 2015, 8(379):ra53

PubMed: 26038598 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6589-606

PubMed: 26258521 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143333

PubMed: 26580964 ( click the link to review the publication )

J Natl Compr Canc Netw, 2013, 11(10):1249-61

PubMed: 24142826 ( click the link to review the publication )

Methods Mol Biol, 2011, 685:91-109

PubMed: 20981520 ( click the link to review the publication )
Expert Opin Pharmacother, 2010, 11(8):1263-76

PubMed: 20429667 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Features

Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.

Targets

L858R/T790M EGFR ^[1] (LoVo cells)	Exon 19 deletion EGFR ^[1] (LoVo cells)	WT EGFR ^[1] (LoVo cells)
11.44 nM	12.92 nM	493.8 nM

In vitro

AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PC-9/BRc1	MlHGSpVv[3Srb36gRZN{[Xl?	MlTsOVAhdk1?	NFjxOmczPCCq	NYjYcmlRTE2VTx?=	MojNbY5lfWOnczDlfJBz\XO\|aX;uJI9nKHSqZTDwdo9ieG:ydH;0bYMhSkOOLUKg[oFucWy7IH3lcYJmeiCESV2=	NIjwb4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|MzPSd-MkW0O\|c{OjV:L3G+
PC-9/ERc1	M{T5eGZ2dmO2aX;uJGF{e2G7	NW\uR2JYPTBibl2=	MlTGNlQhcA>?	NEPU[HlFVVOR	M3THRYlv\HWlZYOg[ZhxemW\|c3nvckBw\iC2aHWgdJJw[XCxcITveIlkKEKFTD2yJIZidWmueTDt[Y1j\XJiQlnN	MknrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N\|I2RC:jPh?=
VP-2	MnvVSpVv[3Srb36gRZN{[Xl?	MXK1NEBvVQ>?	MnvxNlQhcA>?	M{nvNGROW09?	MkD3bY5lfWOnczDlfJBz\XO\|aX;uJI9nKHSqZTDwdo9ieG:ydH;0bYMhSkOOLUKg[oFucWy7IH3lcYJmeiCESV2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
PC-9/BRc1	MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jvXVUxKG6P	Mn3vNVAh\A>?	MmTZSG1UVw>?	NIHWWVRqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIxwdmdvdHXycUApOTBvZHH5LUBoem:5dHigbY5pcWKrdHnvckBie3OjeYO=	NELVbXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|MzPSd-MkW0O\|c{OjV:L3G+
PC-9/ERc1	Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17a[VUxKG6P	MXGxNEBl	NVftOoRYTE2VTx?=	NYfVTFhLcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBtd26pLYTldo0hMDFyLXThfUkh\3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYnz	NV3DNpdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
VP-2	NUnie2Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrZdWo2OCCwTR?=	M{DmZ\|ExKGR?	MYDEUXNQ	NYLCRXB6cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBtd26pLYTldo0hMDFyLXThfUkh\3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYnz	NEnQZok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|MzPSd-MkW0O\|c{OjV:L3G+
PC9 GR4	MYTGeY5kfGmxbjDBd5NigQ>?	M1W5UlAuOTBizszN	NXTWTlNRPzJiaB?=		MWjpcohq[mm2c9MgSWdHWiCyaH;zdIhwenmuYYTpc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7nxsA>	NUnC[pZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFg3OzNpPkK1PVQ5PjN\|PD;hQi=>
PC9	M1TWRWZ2dmO2aX;uJGF{e2G7	M3i3fVAuOTBizszN	NVnDbIt3PzJiaB?=		M1;U[YlvcGmkaYTzJHdVKEWJRmKgZZQhdG:5IHPvcoNmdnS{YYTpc45{	MnvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NEi2N\|MoRjJ3OUS4OlM{RC:jPh?=
PC9 GR4	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LoU\|AuOTBizszN	M{\aVVczKGh?		M1vOT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2OE[zN{c,OjV7NEi2N\|M9N2F-
BAF3	NV65V\|FxTnWwY4Tpc44h[XO\|YYm=		NV7CNXg6PzJiaB?=		NVfmb2VST0l3MDC9JFAvODByMzFOwG0>	NW[zNVBmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	MmPZSpVv[3Srb36gZZN{[Xl?		MVq3NkBp		MlXzS2k2OCB;IECuNFAxOyEQvF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3	NWTVSHFRTnWwY4Tpc44h[XO\|YYm=		MU[3NkBp		MV;HTVUxKD1iMD6wNFEh\|ryP	NGHKcnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	NUXXXWxrTnWwY4Tpc44h[XO\|YYm=		Mn70O\|IhcA>?		MlTwS2k2OCB;IECuNFAyKM7:TR?=	NVW3XYliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9	NUXncIZsTnWwY4Tpc44h[XO\|YYm=		NELv[pQ4OiCq		M{PMVWdKPTBiPTCwMlAxOiEQvF2=	NI\JZ3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3	NH;qUHZHfW6ldHnvckBie3OjeR?=		MUK0JIg>		Mn65SWM2OCB;IECuNFAzKM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827	MkLrSpVv[3Srb36gZZN{[Xl?		NVXCW2c6OyCq		M3XzRWlEPTBiPTCwMlAxOjVizszN	M1jwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEOzPFI6Lz5{N{SzN\|gzQTxxYU6=
H1975	M3fVNmZ2dmO2aX;uJIF{e2G7		NH\veok{KGh?		NIHzPFBKSzVyIE2gNE4xODJ3IN88US=>	NY\wcndRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0N\|M5OjlpPkK3OFM{QDJ7PD;hQi=>
H3255	NV\Jc2ZwTnWwY4Tpc44h[XO\|YYm=		NVnE[G43OyCq		MoPqTWM2OCB;IECuNFA1OSEQvF2=	MnriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2M{O4NlkoRjJ5NEOzPFI6RC:jPh?=
NCI-H1975	NWLjZYNpTnWwY4Tpc44h[XO\|YYm=		M1\H[\|czKGh?		M2HiO2dKPTBiPTCwMlAxPSEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
PC9	NHezWItCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MWC3NkBp		NXHmNo9RUUN3MDC9JFAvODB4NTFOwG0>	NUXvRlRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O\|E3PjRzPD;hQi=>
NCI-H1975	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NEj0XGc4OiCq		NIH5RWRKSzVyIE2gNE4xOTB3IN88US=>	NWjmVmV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O\|E3PjRzPD;hQi=>
Sf21	M3\yUGZ2dmO2aX;uJIF{e2G7				MUnJR\|UxKD1iMD6wNVIh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NkK2O{c,Ojd7OU[yOlc9N2F-
PC9-DRH	MXXGeY5kfGmxbjDhd5NigQ>?		MVqyJIg>		NFP0[YNKSzVyIE2gNE4xOTNizszN	MoLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
BAF3	NUPFbHNMTnWwY4Tpc44h[XO\|YYm=		NEXLO4k4OiCq		M1S3ZWdKPTBiPTCwMlAyOyEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827	NFzub5VHfW6ldHnvckBie3OjeR?=		MUC5OkBp		Mn;KSWM2OCB;IECuNFE1KM7:TR?=	NHXIdFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEKyOVI3QSd-MkiyNlUzPjl:L3G+
HCC827	NXntSGFwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MXi5OkBp		MkjZSWM2OCB;IECuNFE1KM7:TR?=	NGrkcJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
NCI-H1975	Mlu4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MkGwPVYhcA>?		MYLFR\|UxKD1iMD6wNVQh\|ryP	NX7YWYpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
NCI-H1975	NIf0ZnhHfW6ldHnvckBie3OjeR?=		NWLsS5pKOiCq		NEDuUYpKSzVyIE2gNE4xOTVizszN	M1HKOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
H1975	MVXGeY5kfGmxbjDhd5NigQ>?		NY\oXIM5OiCq		MWDJR\|UxKD1iMD6wNVUh\|ryP	NHnGepc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm2PFI2Oyd-Mk[5OlgzPTN:L3G+
PC9	MWXGeY5kfGmxbjDhd5NigQ>?		NWjNb3IxOiCq		M{LvbGlEPTBiPTCwMlAyPyEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
NCI-H1975	NYfuT3dISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M{e0T\|czKGh?		MlLyTWM2OCB;IECuNFE6KM7:TR?=	NInTRmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
NCI-H1975	NXzyWno2TnWwY4Tpc44h[XO\|YYm=		MmPtPVYhcA>?		MoL0SWM2OCB;IECuNFE6KM7:TR?=	NIntXpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEKyOVI3QSd-MkiyNlUzPjl:L3G+
NCI-H1975	NFjGRYFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MkT0PVYhcA>?		MmXmSWM2OCB;IECuNFE6KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZyM{m5NUc,Ojh4MEO5PVE9N2F-
NCI-H1975	NFvwSIpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MYm3NkBp		NEjVVXlKSzVyIE2gNE4xOTlizszN	MmnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN\|QxRC:jPh?=
HCC827	MVLGeY5kfGmxbjDhd5NigQ>?		MlPKNkBp		MojLTWM2OCB;IECuNFI{KM7:TR?=	M37nb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
NCI-H1975	NWP1eYZsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M3O0[FczKGh?		NFLrNI9KSzVyIE2gNE4xOjNizszN	NVj0V49yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
PC9	M2f0PWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NEDlSoU4OiCq		M2\kVWdKPTBiPTCwMlAzOyEQvF2=	NEnIeIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
NCI-H1975	M1qwPWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NG\xOHo4OiCq		MWfHTVUxKD1iMD6wNlQh\|ryP	NX:4V5RRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
HCC827	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NYXKXJM1PzJiaB?=		MX7JR\|UxKD1iMD6wNlU1KM7:TR?=	MonxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3N{[yO\|IoRjJ7NUe2NlczRC:jPh?=
HCC827	MkPyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NHWzdI44OiCq		M1vYZ2lEPTBiPTCwMlAzPyEQvF2=	NFPIcYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
HCC827	NFPySnhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MmXBO\|IhcA>?		MWfJR\|UxKD1iMD6wNlch\|ryP	MmTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN\|QxRC:jPh?=
NCI-H1975	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		Mn7hO\|IhcA>?		NWHBUYRLUUN3MDC9JFAvODNizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|M{W3PUc,OjhyM{O1O\|k9N2F-
H3255	M4DKcmZ2dmO2aX;uJIF{e2G7		M33vcFczKGh?		MorSS2k2OCB;IECuNFM{KM7:TR?=	NWS1V5B4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
H3255	MlfXSpVv[3Srb36gZZN{[Xl?		NUexepBKOiCq		MlXFTWM2OCB;IECuNFM3KM7:TR?=	NHH4foI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
NCI-H1975	MnzWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		Mon3O\|IhcA>?		NXzkUYJYUUN3MDC9JFAvODRzIN88US=>	NFTTXZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUezNFE6Oid-Mkm3N\|AyQTJ:L3G+
NCI-H1975	NHWxT2ZHfW6ldHnvckBie3OjeR?=		MnT0NUBp		NIXJ[WdKSzVyIE2gNE4xPDFizszN	MkjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{S5NlYoRjJ7NUO0PVI3RC:jPh?=
BAF3	MljGSpVv[3Srb36gZZN{[Xl?		NYDtcHB4PCCq		MXnFR\|UxKD1iMD6wOFMh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975	MnjnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M4Tl[VczKGh?		MYLJR\|UxKD1iMD6wOFczKM7:TR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV5NkK3Nkc,Ojl3N{[yO\|I9N2F-
NCI-H1975	NGTQblhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MXq3NkBp		MUTJR\|UxKD1iMD6wOVIh\|ryP	NVO3UpJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN\|E3OzlpPkK3NVMyPjN7PD;hQi=>
PC9	M4fWUGZ2dmO2aX;uJIF{e2G7		NWO1TVljOiCq		MkHITWM2OCB;IECuNFU3KM7:TR?=	M4rPblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
NCI-H1975	Ml3LR5l1d3SxeHnjbZR6KGG\|c3H5		MXe3NkBp		MoL1TWM2OCB;IECuNFYh\|ryP	NXW3XZhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTNpPkK5OFg3QTV\|PD;hQi=>
HCC827	MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?				MmruTWM2OCB;IECuNFYyPiEQvF2=	NEDRWI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
NCI-H1975	NFz2eWRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=				Mlf3TWM2OCB;IECuNFY4KM7:TR?=	NIHJOXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
HaCaT	NWLSb5NiTnWwY4Tpc44h[XO\|YYm=		M1\zSlMhcA>?		MYjJR\|UxKD1iMD6wO\|M4KM7:TR?=	NHP4NWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN\|gzQSd-Mke0N\|M5Ojl:L3G+
NCI-H1975	Mmj4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NV20PFdIPzJiaB?=		NEfzTG1KSzVyIE2gNE4yOyEQvF2=	M17OVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5\|MESyPVk2PjxxYU6=
A431	NHS0bG5HfW6ldHnvckBie3OjeR?=		NVfoe4QyOSCq		MojqTWM2OCB;IECuNVQyKM7:TR?=	NUTpcmNbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
A549	NYGyTnh5TnWwY4Tpc44h[XO\|YYm=				MYTJR\|UxKD1iMD6xOUDPxE1?	NF\JVYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
Calu3	MYLDfZRwfG:6aXPpeJkh[XO\|YYm=		MmnTO\|IhcA>?		MXvHTVUxKD1iMD6yOlQh\|ryP	M1\hUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
Sf9	MXfGeY5kfGmxbjDhd5NigQ>?		NIfkUIszOCCvaX7z		NFH6UlhKSzVyIE2gNE4zPzhizszN	M3;T[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEiyNVUyLz5{OES4NlE2OTxxYU6=
BAF3	NEjQRWVHfW6ldHnvckBie3OjeR?=		MlzpO\|IhcA>?		NEDXTJhIUTVyIE2gNE4{KM7:TR?=	MoDOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
BAF3	NX[xeZZPTnWwY4Tpc44h[XO\|YYm=		NEHWTJc4OiCq		MkPaS2k2OCB;IECuN\|Eh\|ryP	M37CTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H460	M4f3ZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MX:3NkBp		NXTXRYo1UUN3MDC9JFAvPDF3OTFOwG0>	NHLyVnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOlY1OSd-Mki3NVY3PDF:L3G+
LoVo	MWPGeY5kfGmxbjDhd5NigQ>?		MnzyNkBp		Ml70TWM2OCB;IECuOFgh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
LoVo	MY\GeY5kfGmxbjDhd5NigQ>?		MnLNNkBp		NXX2cId6UUN3MDC9JFAvPDhizszN	NUP3[nJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVYzPjdpPkK3PVk3OjZ5PD;hQi=>
A549	M1mzc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M{HweFczKGh?		NELt[3hKSzVyIE2gNE41QDZizszN	NFrsNYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW3OlI4Oid-Mkm1O\|YzPzJ:L3G+
BAF3	NXLYPVFUTnWwY4Tpc44h[XO\|YYm=		NH;MOWk4OiCq		M4fYV2dKPTBiPTCwMlUh\|ryP	NU\GSGN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
A549	MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NYS5SGV4PzJiaB?=		MoPHTWM2OCB;IECuOVMh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O\|M9N2F-
A549	NYWxVoRqS3m2b4TvfIlkcXS7IHHzd4F6		MXO3NkBp		MXPJR\|UxKD1iMD61N{DPxE1?	M136V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEWzN\|QxLz5{OUi1N\|M1ODxxYU6=
BAF3	MmLtSpVv[3Srb36gZZN{[Xl?		M3vnfVczKGh?		NGHkRmNIUTVyIE2gNE42PSEQvF2=	NV;zcZdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	MWfGeY5kfGmxbjDhd5NigQ>?		M4O4XlczKGh?		M1rYNWdKPTBiPTCwMlU3KM7:TR?=	M2r2[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HEK293	M4eySWZ2dmO2aX;uJIF{e2G7				MmPqTWM2OCB;IECuOVch\|ryP	NEXNcGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
BAF3	M2DCXGZ2dmO2aX;uJIF{e2G7		MnPzO\|IhcA>?		M3rDVWdKPTBiPTCwMlU6KM7:TR?=	NGLoNFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
A431	MkDwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?				NUi1cJh7UUN3MDC9JFAvPjF3NjFOwG0>	MmjIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
HT-29	NGDPfHNEgXSxdH;4bYNqfHliYYPzZZk>		NVTCcXRJPzJiaB?=		MnPBTWM2OCB;IECuOlUh\|ryP	Mo\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVMoRjJ7NEi2PVU{RC:jPh?=
A431	M2j1cmZ2dmO2aX;uJIF{e2G7		NXryWWk5QTZiaB?=		MUXFR\|UxKD1iMD62Olch\|ryP	MnzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkWyOlkoRjJ6MkK1NlY6RC:jPh?=
A431	NIPqcFhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		Ml\BPVYhcA>?		Mkm1SWM2OCB;IECuOlch\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
A431	Mnv2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MmGwO\|IhcA>?		MUjJR\|UxKD1iMD62PFUh\|ryP	M3TVeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVI3Lz5{OUWzOFkzPjxxYU6=
A431	Mn;ZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		Mnq4PVYhcA>?		MVPFR\|UxKD1iMD63JO69VQ>?	NFjyeZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[wN\|k6OSd-Mki2NFM6QTF:L3G+
A549	M12wfWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MX:3NkBp		NHXtOIxKSzVyIE2gNE45PyEQvF2=	M1v6bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEi2PVU{Lz5{OUS4Olk2OzxxYU6=
A431	NX7jRmV{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MVK3NkBp		NGGwWlNKSzVyIE2gNE45QTNizszN	Ml;FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{G2N\|koRjJ5MUOxOlM6RC:jPh?=
BA/F3	NUTBb3dqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MofPO\|IhcA>?		NGT3SFRKSzVyIE2gNUDPxE1?	NXXhd\|BzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVg2OjFpPkK2NlU5PTJzPD;hQi=>
BAF3	M2TSZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEfoeoM4OiCq		NY\LfGl1T0l3MDC9JFEvOiEQvF2=	NXLTVHRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H2122	MmLWSpVv[3Srb36gZZN{[Xl?		NEXRZ4E4OiCq		NVvDV4loT0l3MDC9JFEvOiEQvF2=	NHHR[Vc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
A431	NIToXGZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		Ml3NO\|IhcA>?		MWLJR\|UxKD1iMT6yOEDPxE1?	NW\FTVhFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTZpPkOwOFI6QTV4PD;hQi=>
A431	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MofiO\|IhcA>?		MVfJR\|UxKD1iMT6yOkDPxE1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|MEG5Nkc,Ojl5M{CxPVI9N2F-
A431	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NWnMTZhGPzJiaB?=		MV7JR\|UxKD1iMT62NFQh\|ryP	NYrqN444RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN\|M2PzlpPkK4NFM{PTd7PD;hQi=>
A549	MnLBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		Mnn0PVYhcA>?		NFfCfIJGSzVyIE2gNU45OyEQvF2=	NX;hRVBWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
CHL	NH6zS3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYX5Z3MxPzJiaB?=		NVi4XmtGT0l3MDC9JFIvQSEQvF2=	NIXOe\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
H1355	MlTaSpVv[3Srb36gZZN{[Xl?		MknpO\|IhcA>?		NX3i[XE4T0l3MDC9JFMh\|ryP	NWrKcW5jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
H1703	MkjJSpVv[3Srb36gZZN{[Xl?		MX63NkBp		NVvQ[Ig3T0l3MDC9JFMvPSEQvF2=	NWPxelFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
A549	NUKwbZpVTnWwY4Tpc44h[XO\|YYm=		MoDXO\|IhcA>?		M{SwU2dKPTBiPTCzMlUh\|ryP	NEDkOFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
CHO	MlLjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4\IO\|czKGh?		Moe4S2k2OCB;IESuNkDPxE1?	M1vROVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BAF3	M2Wy[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NGC2[Gs4OiCq		NWLCSIFqUUN3MDC9JFQvPjFizszN	Mn3EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
BAF3	M2O4eWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M{LJbVczKGh?		NUTpOJhZUUN3MDC9JFUvOTVizszN	NH3oUIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
BEAS2B	NXexWINmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M4m2[\|czKGh?		Mmq0TWM2OCB;IEG0Mlkh\|ryP	M1uyN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G2OlQyLz5{OEexOlY1OTxxYU6=
NCI-H1975	MYDGeY5kfGmxbjDhd5NigQ>?		NEXCNZozKGh?		MVvJR\|UxKD1iMUWg{txO	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
PC9	NFTs[lZHfW6ldHnvckBie3OjeR?=		M4fBdVIhcA>?		MkfNTWM2OCB;IEG3JO69VQ>?	NHG2WWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
LoVo	MlLwSpVv[3Srb36gZZN{[Xl?		MVuyJIg>		MVfJR\|UxKD1iNEiwJO69VQ>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
NCI-H1975	M2jrdGFvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?=				M1nsZ2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UPVcxVSCmb4XicIUhdXW2YX70JJhmdm:pcnHmeIVlKGmwIGPDTWQhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhOi53IH3nM4toN2SjeTygdI8heWRiZn;yJFch\GG7czDy[YxifGm4ZTD0c{Bkd262cn;s	M2HnR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
rat hepatocytes	M1rMeGZ2dmO2aX;uJIF{e2G7				NHLhcZBKdnS{aX7zbYMh[2ynYYLhcoNmKGmwIILheEBp\XCjdH;jfZRmeyCvZXHzeZJm\CCyZYKgNVAoPiClZXzsdy=>	NYfoZmZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
human hepatocytes	M3nIcGZ2dmO2aX;uJIF{e2G7				MoSxTY51emmwc3njJINt\WG{YX7j[UBqdiCqdX3hckBp\XCjdH;jfZRmeyCvZXHzeZJm\CCyZYKgNVAoPiClZXzsdy=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
NCI-H1975	NFv3XIRCdnSrdIXtc5Ih[WO2aY\peJkh[XO\|YYm=				NWDqfVN2SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q6PzCPIHTveYJt\SCvdYThcpQhgGWwb3fyZYZ1\WRiaX6gV2NKTCCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCB3IH3nM4toN2SjeTygdI8heWRiZn;yJFch\GG7czDy[YxifGm4ZTD0c{Bkd262cn;s	NV7rRVU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
NCI-H1975	MnTvSpVv[3Srb36gZZN{[Xl?				MnLLV4Vt\WO2aY\peJkhcW6mZYisJJJifGmxIH;mJGlEPTBiZn;yJGVITlJiVEe5NG0wVDh3OGKg[I92[mynIH31eIFvfCCneIDy[ZN{cW6pIHj1cYFvKE6FST3INVk4PSClZXzsd{B1dyCLQ{WwJIZweiC5aXzkJJR6eGViRVfGVkBmgHC{ZYPzbY5oKGi3bXHuJGE1OzFiY3XscJM>	MmrVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5M{CxPVIoRjJ7N{OwNVkzRC:jPh?=
NCI-H1975	NGnNdWVCdnSrdIXtc5Ih[WO2aY\peJkh[XO\|YYm=				M3;Eb2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGVITlJiVEe5NG0wVDh3OGKg[I92[mynIH31eIFvfCCneIDy[ZN{cW6pIHj1cYFvKE6FST3INVk4PSClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDCRWxDN2NiYYTofY1q[yCwdXTlJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFExKG2pL3vnMEBxdyCkaXSg[o9zKDJzIHThfZM>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|MEG5Nkc,Ojl5M{CxPVI9N2F-
HCC827	NGfPcmtCeG:ydH;zbZMh[XO\|YYm=				MXrJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDoZZJjd3KrbnegSWdHWiCHN{S2MWE4PTBiZHXs[ZRqd25ibYX0ZY51KGG\|c3Xzd4VlKGG\|IHXhdox6KGGyb4D0c5Rq[yClZXzsd{BifCB\|IIXNJIFnfGW{IEK0JIhzeyCkeTDBco5mgGmwIG[tSmlVSy:ycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJIZtd3diY4n0c41mfHK7IDjSeoIhRSBzLkO0KUk>	MlOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O\|MoRjJ7NE[2O\|c{RC:jPh?=
HCC827	M3ixWWFxd3C2b4Ppd{Bie3OjeR?=				M2fwPWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYuSTd3MDDk[YxmfGmxbjDteZRidnRiYYPz[ZN{\WRiYYOgcIF1\SCjcH;weI91cWNiY3XscJMh[XRiMzD1UUBi\nSncjCyOEBpenNiYomgRY5v\XirbjDWMWZKXENxcILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{eTCoVpZjKD1iMkeuNVQmMQ>?	M3TBe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[2O\|c{Lz5{OUS2Olc4OzxxYU6=
A549	Mkm5SpVv[3Srb36gZZN{[Xl?				MYXT[Yxm[3Srdnn0fUBz[XSrbzDv[kBKSzVyIH\vdkBpfW2jbjDBOVQ6KGOnbHzzJIV5eHKnc4Ppcochf2muZD30fZBmKEWJRmKvT{1T[XNibYX0ZY51KHSxIFnDOVAh\m:{IHj1cYFvKE6FST3INVk4PSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdB?=	MmjXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVMoRjJ7NEi2PVU{RC:jPh?=
HCC827	M1rLV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NHWxUI84OiCq		M{CzZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPDPFI4KGOnbHzzJIF1KDFidV2gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;s	MmXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3N{[yO\|IoRjJ7NUe2NlczRC:jPh?=
BAF3	Mn3RSpVv[3Srb36gZZN{[Xl?		NXnqU4RzOiCq		M2q0[GlvcGmkaYTpc44hd2ZiRVfGVkBVPzlyTT;MPFU5Wi:FN{m3V{BufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSWdHNWmwZIXj[YQhemWlZYD0c5IheGixc4Doc5J6dGG2aX;uJIF1KDFidH:gN{B2VSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEWJRjDzeIlufWyjdHnvckBnd3JiMUWgcYlveyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	Ml\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
BAF3	MkLMSpVv[3Srb36gZZN{[Xl?		M2S1[FIhcA>?		M3jxOGlvcGmkaYTpc44hd2ZiRVfGVkAyQURxVEe5NG0wSzd7N2OgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFXHSk1qdmS3Y3XkJJJm[2WydH;yJJBpd3OyaH;yfYxifGmxbjDheEAyKHSxIEOgeW0heHKnaX7jeYJifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUBGT0Zic4TpcZVt[XSrb36g[o9zKDF3IH3pcpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MkD2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
NCI-H1975	M2HtN2FvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?=				MmrIRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHinbn;ndoFnfGWmIHnuJHNVV0ONLV\vfI4ydnVxTnr1JI52\GVibX;1d4Uh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDndo94fGhiYYSgNlAhdWdxa3ev[IF6NCCybzDx[EBnd3JiMUSg[IF6eyC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?=	M{nl[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{m1NlE6Lz5{OEO5OVIyQTxxYU6=
Caco2	MoO3SpVv[3Srb36gZZN{[Xl?		NUTXSlBXOiCq		M1e4d2Vn\my3eDDyZZRqdyCxZjDhdJBiemWwdDDw[ZJu\WGkaXzpeJkh\nKxbTDiZZNwdGG2ZYLhcEB{cWSnIITvJIFxcWOjbDDzbYRmKG:4ZYKgZZBq[2GuIIPp[IUhfG9iYnHzc4xifGW{YXygd4ll\SCxdnXyJIlvKGi3bXHuJGNi[29{IHPlcIx{KGG2IEWgeW0hcW6ldXLheIVlKG[xcjCyJIhzew>?	Mn\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
A431	MWDGeY5kfGmxbjDhd5NigQ>?				Ml\tV4Vt\WO2aY\peJkhemG2aX:gc4YhTUN3MDDmc5IhcHWvYX6gRVQ{OSClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCHR1\SJJRwKEWFNUCg[o9zKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWi2OOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
Caco2	NXTmN5NmTnWwY4Tpc44h[XO\|YYm=		NWrx[pVvOiCq		NGGxRnFCeHCjcnXueEBx\XKvZXHibYxqfHliYXPyc5N{KGGyaXPhcEB1dyCkYYPvcIF1\XKjbDDzbYRmKGmwIHj1cYFvKEOjY3:yJINmdGy\|IHH0JFUhfU1iaX7jeYJifGWmIH\vdkAzKGi{cx?=	MoW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
Caco2	NYm1UVg1TnWwY4Tpc44h[XO\|YYm=		NXToUWZIOiCq		NX3a[I57SXCyYYLlcpQheGW{bXXhZoltcXS7IHHjdo9{eyCkYYPvcIF1\XKjbDD0c{BieGmlYXygd4ll\SCrbjDoeY1idiCFYXPvNkBk\WyuczDheEA2KHWPIHnuZ5Vj[XSnZDDmc5IhOiCqcoO=	M3;SO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
NCI-H1975	NInLfGxHfW6ldHnvckBie3OjeR?=		NXjiUJJCPCCq		Mle2TY5pcWKrdHnvckBw\iCHR1\SJGw5PTiUL2S3PVBOKG23dHHueEBqdiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFHreEBxcG:\|cHjvdplt[XSrb36gZZQhXGi{M{C4M3NmejR5MzDzbZRmKGG2IEGgeW0hdWWjc4Xy[YQh[W[2ZYKgOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	MlrxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
HCC827	MojjSpVv[3Srb36gZZN{[Xl?		MYG0JIg>		MWPJcohq[mm2aX;uJI9nKEWJRmKg[ZhwdiBzOTDk[YxmfGmxbjDteZRidnRiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFSqckOwPE9U\XJ2N{Ogd4l1\SCjdDCxJJVOKG2nYYP1doVlKGGodHXyJFQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NXrHRWlxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H1975	M4S5OGFxd3C2b4Ppd{Bie3OjeR?=		NUnzTohbPDhiaB?=		NGTzVIpKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO\|kxVSCvdYThcpQh[XO\|ZYPz[YQh[XNiY3HzdIF{\TNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	M3LnTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827	M1;WNGFxd3C2b4Ppd{Bie3OjeR?=		NUXGd\|ZWPDhiaB?=		MnywTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiZYjvckAyQSCmZXzleIlwdiCvdYThcpQh[XO\|ZYPz[YQh[XNiY3HzdIF{\S1\|IHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n	MmPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
PC9	NVznPINDSXCxcITvd4l{KGG\|c3H5		NXztUIIzPDhiaB?=		NHTiW2JKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGDDPUBk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmNTNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	MlvlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H3255	NGn2T\|RCeG:ydH;zbZMh[XO\|YYm=		M3zOPVQ5KGh?		MX7JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEh\|MkW1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSJI12fGGwdDDhd5Nme3OnZDDhd{Bk[XOyYYPlMVMh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd?	NGDxTpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NCI-H1975	NU\BV2xiSXCxcITvd4l{KGG\|c3H5		NWjJNJBoPDhiaB?=		NV;ZZ3J{UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51KGG\|c3Xzd4VlKGG\|IGDBVnAh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd?	NIjnNY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
PC9	M17nWmFxd3C2b4Ppd{Bie3OjeR?=		NVKzemRkPDhiaB?=		NXXDfYZ7UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDQR\|kh[2WubIOgbIFz[m:{aX7nJGVITlJiZYjvckAyQSCmZXzleIlwdiCvdYThcpQh[XO\|ZYPz[YQh[XNiUFHSVEBkdGWjdnHn[UBifCBzIIXNJIFnfGW{IES4JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>?	M3jBe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827	NFywfFRCeG:ydH;zbZMh[XO\|YYm=		MkTCOFghcA>?		NI\LS\|hKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDlfI9vKDF7IHTlcIV1cW:wIH31eIFvfCCjc4Pld5Nm\CCjczDQRXJRKGOuZXH2ZYdmKGG2IEGgeW0h[W[2ZYKgOFghcHK\|IHL5JIludXWwb3Lsc5R1cW6p	M4nBTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H3255	MkDURZBweHSxc3nzJIF{e2G7		MVm0PEBp		M{HHZ2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSEOyOVUh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIhdXW2YX70JIF{e2W\|c3XkJIF{KFCDUmCgZ4xm[X[jZ3WgZZQhOSC3TTDh[pRmeiB2ODDodpMh[nliaX3teY5w[myxdITpcoc>	NUDJWnpXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H1975	MUHGeY5kfGmxbjDhd5NigQ>?				MkXPV4Vt\WO2aY\peJkhemG2aX:gc4YhUUN3MDDmc5IhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQhfG9iSVO1NEBnd3JiaIXtZY4hSTR\|MTDj[YxteyCqYYLic5Jqdmdid3ns[E11gXCnIFXHSnI>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{Nkm5Okc,Ojh2Mk[5PVY9N2F-
human hepatocytes	NIm3fmdHfW6ldHnvckBie3OjeR?=				MVfJcpRzcW6\|aXOgZ4xm[XKjbnPlJIlvKGi3bXHuJIhmeGG2b3P5eIV{KGG\|c3Xzd4VlKHCncjDtbYxtcW:wIHPlcIx{	NWDVeVlnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
rat hepatocytes	M2jIbGZ2dmO2aX;uJIF{e2G7				MnjOTY51emmwc3njJINt\WG{YX7j[UBqdiC{YYSgbIVx[XSxY4n0[ZMh[XO\|ZYPz[YQheGW{IH3pcIxqd25iY3XscJM>	M{L1NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
A549, NCI-H1975	NV3KfXJDTnWwY4Tpc44h[XO\|YYm=				NX7seY52W2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiRVfGMZN1cW23bHH0[YQhf2muZDD0fZBmKEWJRmKgbY4hcHWvYX6gRVU1QSClZXzsd{B1dyCLQ{WwJIZweiCHR1\SJGw5PTiUL2S3PVBOKGSxdXLs[UBufXSjboSgbY4hcHWvYX6gUmNKNUhzOUe1JINmdGy\|	NV:zfnh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
A549, PC9	M2XvSWZ2dmO2aX;uJIF{e2G7				Mk\XV4Vt\WO2aY\peJkhemG2aX:gc4YhUUN3MDDmc5IhTUeILYP0bY12dGG2ZXSge4lt\CC2eYDlJGVITlJiaX6gbJVu[W5iQUW0PUBk\WyuczD0c{BKSzVyIH\vdkBGT0[UIHTlcIV1cW:wIH31eIFvfCCrbjDoeY1idiCSQ{mgZ4VtdHN?	MnfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
HCC827	NE\hbIJCeG:ydH;zbZMh[XO\|YYm=				MnXNTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiRUe0OkB1dyCDN{WwJIRmdGW2aX;uJI12fGGwdDDhd5Nme3OnZDDhd{Bm[XKueTDhdI9xfG:2aXOgZ4VtdHNiYYSgN{B2VSCjZoTldkAzPCCqcoOgZpkhSW6wZYjpckBXNU[LVFOvdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDiZZNm\CCobH;3JIN6fG:vZYTyfUApWn[kIE2gNU4{PCC2bzCxMlY4LSl?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3M{O0NEc,Ojl6NUOzOFA9N2F-
NCI-H1975	MkDuSpVv[3Srb36gZZN{[Xl?				NGDONm1KdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBxcG:\|cHjvdplt[XSrb36gbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGG2IEGgeI8hOTByIH7NJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2R?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTlyNkGxOEc,Ojl7ME[xNVQ9N2F-
A431	NVTG[llDTnWwY4Tpc44h[XO\|YYm=				NYPZXFdFW2WuZXP0bZZqfHlicnH0bY8tKHKjdHnvJGlEPTBiZn;yJIh2dWGwIFG0N\|Eh[2WubIOgc5ZmemW6cILld5Nqdmdid3ns[E11gXCnIFXHSnIhfG9iSVO1NEBnd3JiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIV5eHKnc4PpcochTUeIUjDUO\|kxVS:OOEW4VkBufXSjboS=	NFnxb3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVY{QSd-MkexN\|E3Ozl:L3G+
PC9	M3ztNmFvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?=				M4jEWmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDPUBk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKGGldHn2ZZRqdmdibYX0ZY51KHinbn;ndoFnfGWmIHnuJHNEUURibX;1d4Uh[XO\|ZYPz[YQh[XNidIXtc5Ih\3Kxd4ToJIlvcGmkaYTpc44h[XRiMUCgcYcwc2dxZHH5MEBxdyCzZDDmc5IhPyCmYYnzJJJmdGG2aY\lJJRwKGOxboTyc4w>	MmPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
A431	MlrvRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				MlHvRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUSzNUBk\WyuczD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFUhdWdxa3ev[IF6NCCybzDx[EBnd3JiNzDkZZl{KHKnbHH0bZZmKHSxIHPvcpRzd2x?	MorYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / p-AKT / p-ERK; PubMed: 28416483 Cancer Res PC-9/BRc1 cells were treated with the indicated doses of osimertinib. Drugs were refreshed every 24 hours. Cellular lysates were probed with the indicated antibodies. Osim: osimertinib. ABCB1; PubMed: 27649127 Molecules The effect of osimertinib at 0.3 μM on the expression of ABCB1 was measured in KB-3-1 and KB-C2 cell lines for 0, 24, 48, and 72 h.	28416483 27649127
Growth inhibition assay	Cell viability; PubMed: 31043587 Cell Death Dis Cells were treated with gefitinib or osimertinib for 72 h. Cell viability was measured by MTT assay. P < 0.05, P < 0.01, **P < 0.005 by t-test.	31043587
Immunofluorescence	Ki67 / γH2AX / p16; PubMed: 29212784 EMBO Mol Med PC9ER cells were treated for 5 days with either 3×mAbs (20 μg/ml), saline (CTRL), or with a low dose of osimertinib (2.5 nM). Shown are representative images of cells fixed in paraformaldehyde and immunostained for KI67 (panel E), γH2AX (panel F), and p16 (panel G). DAPI counterstaining was used to follow nuclear localization. Scale bar, 20 μm. The box and whisker plots, where the ends of the box are the upper and lower quartiles, depict quantifications of results obtained in three independent experiments. P ≤ 0.01, *P ≤ 0.001, n = 4; one-way ANOVA with Tukey's test.	29212784

In vivo

AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. ^[2]

Protocol

Animal Research: ^[2]	- Collapse Animal Models: Mice bearing PC9 and H1975 xenograft tumors Dosages: ~5 mg/kg Administration: p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	99 mg/mL warmed (198.15 mM)
	Water	Insoluble
	Ethanol	'43 mg/mL warmed
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	7.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Osimertinib (AZD9291) SDF

Molecular Weight	499.61
Formula	C₂₈ H₃₃ N₇ O₂
CAS No.	1421373-65-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Mereletinib
Smiles	CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02841579	Completed	Drug: Osimertinib	Non-Small Cell Lung Cancer	MedSIR\|AstraZeneca	August 2016	Phase 2
NCT02771314	Unknown status	Drug: AZD9291	Non Small Cell Lung Cancer	Hellenic Oncology Research Group	August 2 2016	Phase 2
NCT02529995	Completed	Drug: AZD9291 40 mg\|Drug: AZD9291 80 mg	Carcinoma Non-Small-Cell Lung With EGFR Mutation Positive	AstraZeneca	August 24 2015	Phase 1
NCT02491944	Completed	Drug: AZD9291\|Drug: [14C]AZD9291	Oncology	AstraZeneca	July 2015	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?
Answer:
Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

EGFR Signaling Pathway Map

Related EGFR Products

Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

Osimertinib (AZD9291)